{"id":"hexavalent-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain, redness, or swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability or fussiness"},{"rate":"5-10","effect":"Drowsiness"},{"rate":"5-10","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hexavalent vaccines typically combine immunogens against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. The vaccine works by presenting inactivated or attenuated antigens that trigger both humoral (antibody) and cell-mediated immune responses, conferring protection against these six diseases with a single injection. This combination approach improves vaccination compliance and reduces the number of injections needed in pediatric immunization schedules.","oneSentence":"A hexavalent vaccine that provides immunization against six infectious diseases by stimulating the immune system to produce antibodies and cellular immunity against multiple pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:44.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infection in infants and children"}]},"trialDetails":[{"nctId":"NCT06950645","phase":"PHASE1","title":"The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-03-27","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT06863142","phase":"PHASE1","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-28","conditions":"Influenza Prevention, Seasonal Influenza","enrollment":45},{"nctId":"NCT05856396","phase":"PHASE4","title":"Maternal Determinants of Infant Immunity to Pertussis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2023-09-12","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Pertussis","enrollment":200},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT06611371","phase":"PHASE1, PHASE2","title":"Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2024-11-12","conditions":"Group B Streptococcal Infections","enrollment":600},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT06967272","phase":"PHASE2","title":"PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-01-20","conditions":"Rotavirus Gastroenteritis","enrollment":400},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT06608199","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","status":"RECRUITING","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2024-11-01","conditions":"Pneumococcal Vaccines, Pneumococcal Infections","enrollment":500},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT06618196","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age","status":"NOT_YET_RECRUITING","sponsor":"LG Chem","startDate":"2024-10-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT06413121","phase":"PHASE3","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-05-06","conditions":"Diptheria Immunization, Tetanus Immunization, Pertussis Immunization","enrollment":1557},{"nctId":"NCT05805618","phase":"EARLY_PHASE1","title":"Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects","status":"UNKNOWN","sponsor":"Syneos Health","startDate":"2024-07-01","conditions":"Gastroenteritis","enrollment":60},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT02697474","phase":"PHASE3","title":"Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT02408926","phase":"PHASE4","title":"Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-04","conditions":"Pertussis","enrollment":370},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03208101","phase":"PHASE1","title":"A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-07-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT03402776","phase":"PHASE3","title":"Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2018-05-01","conditions":"Haemopoietic Stem Cell Transplantation, Allograft","enrollment":200},{"nctId":"NCT00627458","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-01","conditions":"Acellular Pertussis, Diphtheria, Poliomyelitis","enrollment":403},{"nctId":"NCT02610348","phase":"NA","title":"Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-11","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT00316654","phase":"PHASE4","title":"Persistence of Antibody Response to N. Meningitidis Group C in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-02","conditions":"Prevention of Meningococcal Infection","enrollment":489},{"nctId":"NCT00551629","phase":"PHASE2","title":"A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-05","conditions":"Bacterial Infections; Virus Diseases","enrollment":708},{"nctId":"NCT00551915","phase":"PHASE2","title":"A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-05","conditions":"Bacterial Infections; Virus Diseases","enrollment":756},{"nctId":"NCT01111968","phase":"PHASE1","title":"Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-01","conditions":"Influenza","enrollment":266},{"nctId":"NCT00310674","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Prevention of Meningococcal Infection","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"INFLAMMATORY MARKER INCREASED"},{"count":1,"reaction":"INFLUENZA"},{"count":1,"reaction":"INTRAVENTRICULAR HAEMORRHAGE"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"RESPIRATORY SYNCYTIAL VIRUS INFECTION"},{"count":1,"reaction":"RHINOVIRUS INFECTION"},{"count":1,"reaction":"SUPERINFECTION BACTERIAL"}],"_approvalHistory":[],"publicationCount":193,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diphtheria, tetanus, pertussis, hepatitis B,","poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed).","HEXASIIL"],"phase":"marketed","status":"active","brandName":"Hexavalent vaccine","genericName":"Hexavalent vaccine","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"A hexavalent vaccine that provides immunization against six infectious diseases by stimulating the immune system to produce antibodies and cellular immunity against multiple pathogens. Used for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infection in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}